Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
35 results
D2.191 - Tolerogenic Immune Shifts Following PQ Grass 27600 SU Treatment in Seasonal Allergic Rhinitis
D2.194 - Norovirus-Like Particles as Novel Carriers of Hypoallergenic Artemisia vulgaris Allergen Art v 3 for Allergen-Specific Immunotherapy
D2.181 - Managing asthma and allergies during the Russo-Ukrainian war: The damage assessment
D2.182 - Mass Spectrometric Identification of Allergens from Dermatophagoides spp. and Blomia tropicalis in Native, Depigmented and Depigmented-Polymerized Extracts
D2.183 - Differential Sensitization to Goat and Sheep Milk with Partial Tolerance to Cow’s Milk
D2.184 - Sensitization profile to vespid venom: limitations in clinical practice
D2.186 - In vivo and ex vivo evaluation of the immunological responses induced by a grass depigmented-polymerized allergenic extract in dogs
D2.187 - Are Component-Based Skin Tests Reliable? Correlation between Skin Prick Testing and Specific IgE to Der p 1, Der p 2 and Der p 23
D2.188 - Spectrum of Sensitization to Respiratory Allergens in Patients in the Republic of Kazakhstan
D2.190 - Evaluation of a commercially available Birch Pollen Extract for its suitability in Nasal Allergen Challenges: Feasibility and Dose-Response Assessment
D2.192 - Comparison of the Multiplex ALEX Method and Single-Plex ImmunoCAP Method in the Diagnosis of Seasonal Allergic Rhinitis in Adults Caused by Birch Pollen
D2.193 - Real-World Effectiveness of Allergen Immunotherapy in Polysensitized Patients: A Retrospective Study of 260 Cases
D2.195 - AIT prescription drivers: a cluster analysis of data from the CHOICE survey
D3.418 - A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects
D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset
D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study
D3.421 - Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)
D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes
D3.423 - Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study
D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download